First of Its Kind in the Region: KFSHRC Successfully Performs Endoscopic Sleeve Gastroplasty on Kidney Transplant Patient
RIYADH, Saudi Arabia, June 12, 2025 (GLOBE NEWSWIRE) — In a medical achievement considered the first of its kind in the region, King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh has successfully performed an endoscopic sleeve gastroplasty (ESG) on a patient who had previously undergone a kidney transplant, a case that requires meticulous management of immunosuppressive medications and the prevention of any complications that could jeopardize the transplanted organ. This procedure marks a significant advancement in providing safe treatment solutions for transplant recipients, to improve their graft survival and quality of life.
Known as Endoscopic Sleeve Gastroplasty (ESG), the procedure differs from surgical sleeve gastrectomy in that it requires no abdominal incisions, which is important for transplant patients. Instead, it uses an endoscope inserted through the mouth to suture the stomach internally, effectively reducing its volume and enabling the patient to lose weight and improve overall health.
The procedure aimed to address obesity and metabolic, which are among the leading factors that can negatively impact the health of a transplanted kidney, increase cardiovascular risk, and reduce long-term patient outcomes.
The procedure was performed by a multidisciplinary team of medical experts, led by Dr. Ehab Abufarhaneh, Consultant in Adult Transplant Gastroenterology and Hepatology. The team included gastroenterologists, an upper GI surgeon, transplant surgeons, transplant Nephrology, and transplant anaesthesiologists, all supported by highly trained nursing staff to ensure the highest level of safety, with particular focus on managing the patient's immunosuppressive regimen—critical to preserving kidney graft function.
This achievement underscores the pivotal role of KFSHRC's Organ Transplant Centre of Excellence as a leading medical environment capable of delivering precise interventions for complex transplant cases. By adopting innovative techniques tailored to the unique needs of transplant patients and developing treatment protocols that address post-transplant challenges, the centre reinforces its position as a regional referral hub for cases beyond the scope of conventional treatment pathways.
The success of this procedure further exemplifies KFSHRC's ongoing commitment to delivering advanced, patient-centred healthcare and fulfilling its vision of being the optimal choice for patients supported by an integrated ecosystem of education, research, and clinical excellence that aligns with the ambitions of Saudi Arabia's health sector.
It is noteworthy that KFSHRC has been ranked first in the Middle East and North Africa and 15th globally in the list of the world's top 250 Academic Medical Centres for the third consecutive year and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine. For more information, visit
www.kfshrc.edu.sa
or contact our media team at
mediacoverage@kfshrc.edu.sa
.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/e683bcda-0992-4aff-aa47-5664815d432c
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Analysis of the European Hospitals Market 2025-2030: Investment Opportunities for Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Sweden, Belgium, and Ireland
The market is poised for growth, driven by aging demographics, technological advances, and a shift to value-based care. Key opportunities lie in digital health, infrastructure upgrades, and workforce development. Addressing workforce shortages and integrating value-based models will be crucial for sustainability. European Hospital Market Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Europe Hospital Market, By Country, Competition, Forecast and Opportunities, 2020-2030F" has been added to offering. The Europe Hospital Market was valued at USD 0.85 Trillion in 2024, and is expected to reach USD 1.09 Trillion by 2030, rising at a CAGR of 4.35%. This mature and advanced market is anchored by strong public healthcare systems, cutting-edge infrastructure, and a widespread commitment to universal care access. The sector's growth is being fueled by shifting demographics, especially aging populations, along with rapid technological progress and evolving patient expectations. To maintain performance and meet rising demand, hospitals are undergoing digital transformation, expanding service capacity, and focusing on operational modernization. Investments in digital health, workforce development, and facility upgrades are becoming critical. Meanwhile, the shift toward integrated, value-based care models is redefining hospital operations and emphasizing efficiency, outcome measurement, and long-term sustainability, ensuring hospitals remain central to Europe's healthcare landscape. Key Market Driver Aging Population and Chronic Disease Burden Europe's aging population and the resulting increase in chronic diseases are major factors propelling the hospital market. By 2030, the number of Europeans living with Alzheimer's and related dementias is expected to rise to 14 million, escalating the healthcare system's financial and operational demands. The projected economic impact of Alzheimer's care is set to exceed USD 721.37 billion by 2050. As per Eurostat, individuals aged 65 and older made up 21.1% of the EU's population in 2022, and this is forecasted to rise to 32.5% by 2100. Older populations are more prone to conditions such as cardiovascular disease, diabetes, osteoporosis, neurodegenerative disorders, and cancer, all of which increase hospital care needs. Consequently, hospitals are expanding geriatric and chronic care services, modernizing infrastructure, and adapting clinical operations to manage growing patient loads. Key Market Challenge Workforce Shortages and Talent Retention The shortage of skilled medical professionals - including nurses, general practitioners, and specialists - poses a significant challenge for hospitals across Europe. Contributing factors include an aging healthcare workforce, burnout, and early retirements, particularly in under-resourced public systems. Staffing shortages reduce care quality, extend wait times, and hinder hospitals' ability to scale operations or adopt innovative models. The increased use of temporary staffing and overtime also inflates labor costs. Addressing this challenge requires strategic investment in training programs, international recruitment, and adoption of automation technologies such as AI-driven diagnostics and robotic procedures to ease clinical burdens and improve workforce efficiency. Key Market Trend Integration of Value-Based Healthcare Models European hospitals are transitioning from fee-for-service to value-based healthcare (VBHC) models, which emphasize care quality, patient outcomes, and cost-effectiveness. Government mandates and payer incentives are accelerating this shift to improve healthcare delivery and financial sustainability. Hospitals are redesigning care pathways around bundled, patient-centered services with a focus on chronic disease management, preventative care, and post-discharge support. The implementation of performance-based KPIs is reshaping reimbursement models, promoting efficiency, and reducing readmissions. Advanced analytics and predictive tools are increasingly used to track outcomes, manage resources, and demonstrate value - ultimately strengthening hospitals' competitiveness and long-term viability in the evolving European health ecosystem. Key Market Players Profiled: HCA Healthcare UK Fresenius SE & Co. KGaA Spire Healthcare Group plc Orpea Group Asklepios Klinik Barmbek Sana Kliniken AG San Donato Group (Gruppo San Donato) Report Scope In this report, the Europe Hospital Market has been segmented into the following categories: Europe Hospital Market, By Product: Public Private Europe Hospital Market, By Type: General Specialty Multi-Speciality Europe Hospital Market, By Type of Services: In-Patient Services Out-Patient Services Europe Hospital Market, By Bed Capacity: Up to 100 beds 100-500 beds Above 500 beds Europe Hospital Market, By Country: Germany France United Kingdom Italy Spain Netherlands Switzerland Sweden Belgium Ireland Key Attributes Report Attribute Details No. of Pages 125 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $0.85 Trillion Forecasted Market Value (USD) by 2030 $1.09 Trillion Compound Annual Growth Rate 4.3% Regions Covered Europe For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment European Hospital Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Analysis of the European Hospitals Market 2025-2030: Investment Opportunities for Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Sweden, Belgium, and Ireland
The market is poised for growth, driven by aging demographics, technological advances, and a shift to value-based care. Key opportunities lie in digital health, infrastructure upgrades, and workforce development. Addressing workforce shortages and integrating value-based models will be crucial for sustainability. European Hospital Market Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Europe Hospital Market, By Country, Competition, Forecast and Opportunities, 2020-2030F" has been added to offering. The Europe Hospital Market was valued at USD 0.85 Trillion in 2024, and is expected to reach USD 1.09 Trillion by 2030, rising at a CAGR of 4.35%. This mature and advanced market is anchored by strong public healthcare systems, cutting-edge infrastructure, and a widespread commitment to universal care access. The sector's growth is being fueled by shifting demographics, especially aging populations, along with rapid technological progress and evolving patient expectations. To maintain performance and meet rising demand, hospitals are undergoing digital transformation, expanding service capacity, and focusing on operational modernization. Investments in digital health, workforce development, and facility upgrades are becoming critical. Meanwhile, the shift toward integrated, value-based care models is redefining hospital operations and emphasizing efficiency, outcome measurement, and long-term sustainability, ensuring hospitals remain central to Europe's healthcare landscape. Key Market Driver Aging Population and Chronic Disease Burden Europe's aging population and the resulting increase in chronic diseases are major factors propelling the hospital market. By 2030, the number of Europeans living with Alzheimer's and related dementias is expected to rise to 14 million, escalating the healthcare system's financial and operational demands. The projected economic impact of Alzheimer's care is set to exceed USD 721.37 billion by 2050. As per Eurostat, individuals aged 65 and older made up 21.1% of the EU's population in 2022, and this is forecasted to rise to 32.5% by 2100. Older populations are more prone to conditions such as cardiovascular disease, diabetes, osteoporosis, neurodegenerative disorders, and cancer, all of which increase hospital care needs. Consequently, hospitals are expanding geriatric and chronic care services, modernizing infrastructure, and adapting clinical operations to manage growing patient loads. Key Market Challenge Workforce Shortages and Talent Retention The shortage of skilled medical professionals - including nurses, general practitioners, and specialists - poses a significant challenge for hospitals across Europe. Contributing factors include an aging healthcare workforce, burnout, and early retirements, particularly in under-resourced public systems. Staffing shortages reduce care quality, extend wait times, and hinder hospitals' ability to scale operations or adopt innovative models. The increased use of temporary staffing and overtime also inflates labor costs. Addressing this challenge requires strategic investment in training programs, international recruitment, and adoption of automation technologies such as AI-driven diagnostics and robotic procedures to ease clinical burdens and improve workforce efficiency. Key Market Trend Integration of Value-Based Healthcare Models European hospitals are transitioning from fee-for-service to value-based healthcare (VBHC) models, which emphasize care quality, patient outcomes, and cost-effectiveness. Government mandates and payer incentives are accelerating this shift to improve healthcare delivery and financial sustainability. Hospitals are redesigning care pathways around bundled, patient-centered services with a focus on chronic disease management, preventative care, and post-discharge support. The implementation of performance-based KPIs is reshaping reimbursement models, promoting efficiency, and reducing readmissions. Advanced analytics and predictive tools are increasingly used to track outcomes, manage resources, and demonstrate value - ultimately strengthening hospitals' competitiveness and long-term viability in the evolving European health ecosystem. Key Market Players Profiled: HCA Healthcare UK Fresenius SE & Co. KGaA Spire Healthcare Group plc Orpea Group Asklepios Klinik Barmbek Sana Kliniken AG San Donato Group (Gruppo San Donato) Report Scope In this report, the Europe Hospital Market has been segmented into the following categories: Europe Hospital Market, By Product: Public Private Europe Hospital Market, By Type: General Specialty Multi-Speciality Europe Hospital Market, By Type of Services: In-Patient Services Out-Patient Services Europe Hospital Market, By Bed Capacity: Up to 100 beds 100-500 beds Above 500 beds Europe Hospital Market, By Country: Germany France United Kingdom Italy Spain Netherlands Switzerland Sweden Belgium Ireland Key Attributes Report Attribute Details No. of Pages 125 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $0.85 Trillion Forecasted Market Value (USD) by 2030 $1.09 Trillion Compound Annual Growth Rate 4.3% Regions Covered Europe For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment European Hospital Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Report: Multispecific Antibodies Market to Surpass USD 50 Billion by 2030
Explore the booming Global Multispecific Antibodies Market set to surpass USD 50 billion by 2030. Key highlights include sales insights, approved drugs, and clinical trials from over 700 antibodies. Significant contributors like Roche and rising players ensure ongoing innovation in this dynamic biopharma sector. Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Global Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Insight 2030" report has been added to Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Insight 2030 Report Highlights: Global Multispecific Antibodies Market Opportunity By 2030: > USD 50 Billion Global Multispecific Antibodies Market Sales In 2024: > USD 12 Billion Number Of Approved Multispecific Antibodies: 18 Global & Regional Trends Insight Approved Antibodies Global, Regional, Annual & Quarterly Sales Insight Approved Antibodies Dosage & Pricing Insight Comprehensive Insight On All Antibodies In Clinical Trials By Company, Country, Indication & Phase Number Of Multispecific Antibodies: In Clinical Trials: > 700 Multispecific antibodies market globally has been one of the most energetic and fast growing sectors in the biopharmaceutical business as a result of therapeutic breakthroughs and growing acceptance of their ability to treat complicated pathologies by targeting multiple pathways simultaneously. As of May 2025, 18 multispecific antibodies have gained regulatory approval globally, all of which are bispecific constructs, a monumental milestone in the history of targeted therapeutics. This expanding portfolio boasts trailblazing drugs like Blincyto, the first bispecific antibody to gain approval, and Hemlibra, which was the first bispecific antibody to be approved for a non-cancer indication. The latest entrant to this therapeutic pipeline is Regeneron's Lynozyfic, which received marketing approval in April 2025 for the treatment of multiple myeloma, with evidence of ongoing momentum in the segment. The range of approved multispecific antibodies mirrors the flexibility of this therapeutic modality across various disease indications and patient bases. Rybrevant is another key breakthrough as the first bispecific antibody for a solid tumor, whereas China based Akeso's Cadonilimab is especially noteworthy for being solely approved bispecific antibody intended to target two immune checkpoints at once and becoming the first China developed bispecific antibody to gain regulatory approval. This regional variation in development emphasizes the world nature of innovation in this sector, with input from both mature pharmaceutical markets and developing biotechnology centers. The regulatory environment is still changing at a rapid pace, with further approvals expected in the near future. The FDA is also evaluating marketing applications for Odronextamab and Linvoseltamab, both of which have already received approval in the EU for follicular lymphoma and diffuse large B-cell lymphoma, and multiple myeloma, respectively. Such transatlantic regulatory advancements reflect the growing acceptability and trust in multispecific antibody technologies by global regulatory bodies. Market performance has been extremely strong, with global multispecific antibodies market sales in 2024 amounting to over US$ 12.6 Billion, followed by first quarter 2025 sales of over US$ 3.46 Billion. The US is the largest contributor to these sales, highlighting the maturity and acceptance of the market in this prime geography. Roche's mature products, Hemlibra and Vabysmo, lead the market share, with over half of total sales, emphasizing the value of first mover benefit and effective market entry strategies in this competitive market. The pipeline for development is an even more daunting picture, with more than 900 multispecific antibodies already in various stages of development. Oncology is leading this pipeline, both due to the traditional priority of multispecific antibody development and due to the large unmet medical needs in cancer treatment. However, pipeline diversity is not confined to oncology alone with promising candidates being identified in autoimmune and inflammatory diseases and neurological disorders as well, indicating an expanding therapeutic horizon that has the potential to dramatically expand market opportunities. Major industry players behind this innovation are well established pharma giants like Amgen, AstraZeneca, Genentech, and Regeneron, as well as new biotech firms like ABL Bio, Harbour BioMed, Innovent Biologics, Merus, and Zymeworks. This combination of well established and new players provides a vibrant competitive landscape that ensures ongoing innovation and technological progress. Strategic alliances continue to influence the development of the market, such as in the April 2025 alliance of Boehringer Ingelheim and Cue Biopharma for the development of CUE-501, a bispecific candidate that attacks pathogenic B cells via virus-specific memory T cells. The alliance, involving a US$ 12 Million upfront payment and possible milestone payments of up to US$ 345 Million, illustrates the high financial investment that companies are undertaking to drive multispecific antibody technologies, specifically in autoimmune indications where existing treatments are still inadequate. Regulatory encouragement of innovation continues to be robust, with the FDA's April 2025 fast track designation of ISB 2001, an Ichnos Glenmark Innovation investigational trispecific T-cell engager for relapsed or refractory multiple myeloma, reflecting ongoing regulatory enthusiasm for moving multispecific antibody technologies forward that treat important unmet medical needs. As a result of these ongoing innovations, the global multispecific antibody market is expected to grow rapidly and is on track to become one of the most important segments within the pharmaceutical industry. Key Topics Covered: 1. Introduction to Next Generation Multispecific Antibodies 2. Next Generation Multispecific Antibody Current Clinical Development & Future Commercialization Outlook2.1 Current Market Overview2.2 Future Commercialization Opportunity2.3 Collaborations, License Agreements, Investments & Acquisitions2.4 Next Generation Multispecific Antibody Proprietary Technologies By Company 3. Next Generation Multispecific Antibody Clinical Trends by Indication3.1 Cancer3.2 Hematological Disorders3.3 Microbial Infections3.4 Autoimmune & Inflammatory Disorders3.5 Ocular Diseases 4. Next Generation Multispecific Antibody Clinical Development & Market Trends by Region4.1 US4.2 EU4.3 China4.4 UK4.5 Japan4.6 Australia4.7 South Korea4.8 Canada 5. Approved Multispecific Antibodies - Clinical Overview, Pricing & Dosage Insight5.1 Overview5.2 Clinical Overview, Pricing & Dosage Insight 6. Approved Multispecific Antibodies - Sales Insight (2020 - Q1'2025) 7. Global Multispecific Antibodies Clinical Trials Overview 8. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase8.1 Research8.2 Preclinical8.3 Phase-I8.4 Phase-I/II8.5 Phase-II8.6 Phase-II/III8.7 Phase-III8.8 Preregistration8.9 Registered 9. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication 10. Global Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase10.1 Research10.2 Preclinical10.3 Phase I10.4 Phase I/II10.5 Phase II/III 11. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase11.1 Preclinical11.2 Phase I11.3 Phase I/II11.4 Phase II 12. Competitive Landscape AbbVie ABL Bio Abzyme Therapeutics Affimed Therapeutics Akeso Biopharma Alligator Bioscience Amgen Antibody Therapeutics APITBIO Astellas Pharma AstraZeneca Aptevo Therapeutics BioAtla Biocytogen Pharmaceuticals Biosion EpimAb Biotherapeutics FutureGen Biopharmaceutical Genentech Genmab Genor Biopharma Gensun Biopharma Harbour BioMed IGM Biosciences I-MAB Biopharma ImmuneOnco Biopharma ImmunoPrecise Antibodies Innate Pharma Innovent Biologics Invenra Johnson & Johnson Kenjockety Biotechnology LaNova Medicines Limited Light Chain Bioscience Linton Pharm Lyvgen Biopharma MacroGenics Merck Merus ModeX Therapeutics (OPKO Health) Molecular Partners NovaRock Biotherapeutics Numab OPKO Health Pfizer Regeneron Pharmaceuticals Revitope Roche Sanofi Sichuan Baili Pharmaceutical SystImmune Virtuoso Therapeutics Xencor Y-Biologics Zhejiang Shimai Pharmaceutical Zymeworks For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
